Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP, Chief Financial Officer | July 01, 2026 | July 02, 2026 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | EVP, Chief Financial Officer | November 25, 2020 | December 01, 2020 |
| Tango Therapeutics, Inc.TNGX · Entity 1497 | Director | June 05, 2026 | June 08, 2026 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP & Chief Financial Officer | March 27, 2024 | March 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,221 |
Ending reported balance
After 2026-07-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-01 · Exercise / conversion · Acquired 1,112 · Balance 64,333 Row 2 · 2026-07-01 · Sale · Disposed 1,112 · Balance 63,221 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.51 · Expires 2034-05-30 | Direct | 26,709 |
Reported balance
After 2026-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-01 · Exercise / conversion · Disposed 1,112 · Balance 26,709 |
SANGAMO THERAPEUTICS, INC
Report date November 25, 2020 · Filed December 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,708 |
Reported balance
After 2020-11-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-25 · Tax withholding · Disposed 5,042 · Balance 88,708 F1: Represents shares underlying the portion of the restricted stock unit grant that vested on November 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on November 25, 2020 of $9.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2: Includes: 9,540 shares resulting from the November 25, 2020 vesting of Reporting Person's November 25, 2019 restricted stock unit ("RSU") grant; 29,168 shares subject to such RSU grant that will vest in two remaining annual installments on November 25, 2021 and 2022, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date; 50,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2020. All such RSUs vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the dates of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying the portion of the restricted stock unit grant that vested on November 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on November 25, 2020 of $9.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended").
F2: Includes: 9,540 shares resulting from the November 25, 2020 vesting of Reporting Person's November 25, 2019 restricted stock unit ("RSU") grant; 29,168 shares subject to such RSU grant that will vest in two remaining annual installments on November 25, 2021 and 2022, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date; 50,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2020. All such RSUs vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the dates of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.
Tango Therapeutics, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,870 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 570 · Balance 22,870 F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.22 · Expires 2036-06-05 | Direct | 3,570 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 3,570 · Balance 3,570 F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Vir Biotechnology, Inc.
Report date March 27, 2024 · Filed March 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,492 |
Reported balance
After 2024-03-27 transaction · row 1
1 source rowRow 1 · 2024-03-27 · Sale · Disposed 6,008 · Balance 100,492 F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 21:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 1,112 | $0.00 Strike: $48.51 | $0.00 |
DisclosureSEC source: 0001061983-26-000072 · form4.xml · derivative · entry 3 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,709 Underlying: Common Stock · 1,112 shares Expires 2034-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,112 | $87.79 | $97,622.48 |
DisclosureSEC source: 0001061983-26-000072 · form4.xml · nonDerivative · entry 2 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,221 Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,112 | $48.51 | $53,943.12 |
DisclosureSEC source: 0001061983-26-000072 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 823 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001061983-26-000070 · form4.xml · derivative · entry 11 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,681 Underlying: Common Stock · 823 shares Expires 2035-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 188 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001061983-26-000070 · form4.xml · derivative · entry 10 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,640 Underlying: Common Stock · 188 shares Expires 2035-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 1,113 | $0.00 Strike: $48.51 | $0.00 |
DisclosureSEC source: 0001061983-26-000070 · form4.xml · derivative · entry 9 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,304 Underlying: Common Stock · 1,113 shares Expires 2034-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 822 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001061983-26-000070 · form4.xml · derivative · entry 8 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,504 Underlying: Common Stock · 822 shares Expires 2035-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 188 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001061983-26-000070 · form4.xml · derivative · entry 7 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,828 Underlying: Common Stock · 188 shares Expires 2035-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,134 | $85.00 | $266,390.00 |
DisclosureSEC source: 0001061983-26-000070 · form4.xml · nonDerivative · entry 6 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,221 Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 823 | $44.36 | $36,508.28 |
DisclosureSEC source: 0001061983-26-000070 · form4.xml · nonDerivative · entry 5 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 188 | $44.36 | $8,339.68 |
DisclosureSEC source: 0001061983-26-000070 · form4.xml · nonDerivative · entry 4 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,113 | $48.51 | $53,991.63 |
DisclosureSEC source: 0001061983-26-000070 · form4.xml · nonDerivative · entry 3 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 822 | $44.36 | $36,463.92 |
DisclosureSEC source: 0001061983-26-000070 · form4.xml · nonDerivative · entry 2 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 188 | $44.36 | $8,339.68 |
DisclosureSEC source: 0001061983-26-000070 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 1,113 | $0.00 Strike: $48.51 | $0.00 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · derivative · entry 15 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,821 Underlying: Common Stock · 1,113 shares Expires 2034-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 822 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · derivative · entry 14 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,197 Underlying: Common Stock · 822 shares Expires 2035-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 188 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · derivative · entry 13 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,011 Underlying: Common Stock · 188 shares Expires 2035-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 1,113 | $0.00 Strike: $48.51 | $0.00 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · derivative · entry 12 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,934 Underlying: Common Stock · 1,113 shares Expires 2034-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 2,817 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · derivative · entry 11 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,199 Underlying: Common Stock · 2,817 shares Expires 2035-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 9,307 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · derivative · entry 10 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,019 Underlying: Common Stock · 9,307 shares Expires 2035-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 23,370 | $0.00 Strike: $48.51 | $0.00 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · derivative · entry 9 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,047 Underlying: Common Stock · 23,370 shares Expires 2034-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 38,730 | $82.30 | $3,187,479.00 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · nonDerivative · entry 8 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,221 Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,113 | $48.51 | $53,991.63 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · nonDerivative · entry 7 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 822 | $44.36 | $36,463.92 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · nonDerivative · entry 6 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 188 | $44.36 | $8,339.68 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · nonDerivative · entry 5 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,113 | $48.51 | $53,991.63 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · nonDerivative · entry 4 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,817 | $44.36 | $124,962.12 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · nonDerivative · entry 3 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 9,307 | $44.36 | $412,858.52 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · nonDerivative · entry 2 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2026 Filed Jun 29, 2026 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 23,370 | $48.51 | $1,133,678.70 |
DisclosureSEC source: 0001061983-26-000071 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 21:49 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 3,570 | $0.00 Strike: $20.22 | $0.00 |
DisclosureSEC source: 0001193125-26-262172 · ownership.xml · derivative · entry 2 Lee Sung · CIK 0001793200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,570 Underlying: Common Stock · 3,570 shares Expires 2036-06-05 F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 21:49 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 570 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-262172 · ownership.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,870 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| May 05, 2026 Filed May 5, 2026 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 23,906 | $76.87 | $1,837,654.22 |
DisclosureSEC source: 0001061983-26-000049 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,221 Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:26 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 5,200 | $0.00 Strike: $22.06 | $0.00 |
DisclosureSEC source: 0001193125-26-201749 · ownership.xml · derivative · entry 2 Lee Sung · CIK 0001793200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2036-04-29 F2 · derivative.exercise_date: This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years commencing on January 2, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. The options were granted in connection with the Reporting Person's service on the Issuer's board of directors and reflect the value the Reporting Person is entitled to pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| April 29, 2026 Filed May 1, 2026 21:26 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 12,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-201749 · ownership.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,300 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments on January 2, 2027, January 2, 2028 and January 2, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. The RSUs were granted in connection with the Reporting Person's service on the Issuer's board of directors and reflect the value the Reporting Person is entitled to pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 21:46 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,935 | $62.15 | $306,710.25 |
DisclosureSEC source: 0001061983-26-000029 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,127 F1 · kind: Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 29,480 | $0.00 Strike: $60.06 | $0.00 |
DisclosureSEC source: 0001061983-26-000021 · form4.xml · derivative · entry 3 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,480 Underlying: Common Stock · 29,480 shares Expires 2036-03-14 F3 · kind: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (Right to Buy) · Derivative | 1,665 | $0.00 Strike: $60.06 | $0.00 |
DisclosureSEC source: 0001061983-26-000021 · form4.xml · derivative · entry 2 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,665 Underlying: Common Stock · 1,665 shares Expires 2036-03-14 F2 · kind: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 20,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-26-000021 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,062 F1 · kind: Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:10 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001193125-26-004433 · ownership.xml · derivative · entry 2 Lee Sung · CIK 0001793200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-02 F2 · derivative.exercise_date: This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:10 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004433 · ownership.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 805 | $62.72 | $50,489.60 |
DisclosureSEC source: 0001061983-25-000053 · form4.xml · nonDerivative · entry 3 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,416 F3 · kind: Shares withheld for tax withholding upon vesting of performance shares. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 2,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-25-000053 · form4.xml · nonDerivative · entry 2 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,221 F2 · kind: Performance shares earned upon achievement of performance goal. Shares vested immediately. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 2,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-25-000053 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,069 F1 · kind: Performance shares earned upon achievement of performance goal. Shares remain subject to 1-year time vesting requirement. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 1,560 | $65.02 | $101,431.20 |
DisclosureSEC source: 0001061983-25-000046 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,917 F1 · kind: Sell to cover transaction for tax withholding upon vesting of Performance Stock Units granted earned on December 2, 2024. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 4,965 | $31.21 | $154,957.65 |
DisclosureSEC source: 0001127602-25-016416 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,477 F1 · kind: Transactions represent withholding of restricted stock units upon vesting of 13,874 restricted stock units. Reporting person received 8,909 net shares of common stock after the withholding transaction.. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 41,326 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009770 · form4.xml · derivative · entry 3 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,326 Underlying: Common Stock · 41,326 shares Expires 2035-03-13 F3 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Lee's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (Right to Buy) · Derivative | 9,016 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009770 · form4.xml · derivative · entry 2 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,016 Underlying: Common Stock · 9,016 shares Expires 2035-03-13 F2 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Lee's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:24 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 32,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-009770 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,442 F1 · kind: Comprised of restricted stock units that convert to shares of common stock on a 1:1 basis upon vesting. 40% of the RSUs will vest on the 1-year anniversary of the date of grant; an additional 40% of the RSUs will vest on the 2-year anniversary of the date of grant; and the final 20% of the RSUs will vest on the 3-year anniversary of the date of grant, in each case subject to Mr. Lee's continued employment with the company on the scheduled vesting date. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:30 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 4,304 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028721 · form4.xml · nonDerivative · entry 3 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,755 F3 · kind: Transaction represents shares of PSUs whose performance condition was satisfied but that remain subject to time-based vesting. These PSUs to vest in full December 3, 2025. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:30 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 1,536 | $51.51 | $79,119.36 |
DisclosureSEC source: 0001127602-24-028721 · form4.xml · nonDerivative · entry 2 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,451 F2 · kind: Transaction represents withholding of shares to satisfy grantee's tax obligations in connection with vesting PSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.